Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
43
HUM Quote, Financials, Valuation and Earnings
Last price:
$257.90
Seasonality move
:
0.44%
Day range:
$258.26 - $262.73
52-week range:
$206.87 - $315.35
Dividend yield:
1.37%
P/E ratio:
24.31x
P/S ratio:
0.25x
P/B ratio:
1.68x
Volume:
1.9M
Avg. volume:
1.6M
1-year change:
10.02%
Market cap:
$31.2B
Revenue:
$117.8B
EPS (TTM):
$10.67
Analysts' Opinion
-
Consensus RatingHumana, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 16 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $287.83, Humana, Inc. has an estimated upside of 10.96% from its current price of $259.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $215.00 representing 17.12% downside risk from its current price of $259.40.
Fair Value
-
According to the consensus of 24 analysts, Humana, Inc. has 10.96% upside to fair value with a price target of $287.83 per share.
HUM vs. S&P 500
-
Over the past 5 trading days, Humana, Inc. has underperformed the S&P 500 by -3.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Humana, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Humana, Inc. has grown year-over-year revenues for 32 quarters straight. In the most recent quarter Humana, Inc. reported revenues of $32.6B.
Earnings Growth
-
Humana, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Humana, Inc. reported earnings per share of $1.62.
Enterprise value:
43.9B
EV / Invested capital:
1.41x
Price / LTM sales:
0.25x
EV / EBIT:
25.74x
EV / Revenue:
0.35x
PEG ratio (5yr expected):
--
EV / Free cash flow:
28.36x
Price / Operating cash flow:
20.24x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
2.62%
Net Income Margin (TTM):
1.03%
Return On Equity:
7.3%
Return On Invested Capital:
4.25%
Operating Margin:
1.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $102.4B | $115B | $126.4B | $29.4B | $32.6B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $4.5B | $2.8B | $3B | $728M | $400M | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $24.12 | $11.29 | $10.67 | $3.97 | $1.62 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.8B | $33.7B | $38.3B | $32.9B | $32.8B | |
| Total Assets | $45.3B | $50.8B | $55.9B | $50B | $49.7B | |
| Current Liabilities | $15B | $25.1B | $27.8B | $18.7B | $16.2B | |
| Total Liabilities | $29B | $34.4B | $38.9B | $32.4B | $31.1B | |
| Total Equity | $16.3B | $16.3B | $17B | $17.6B | $18.6B | |
| Total Debt | $11.5B | $7.8B | $9.5B | $11.9B | $12.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6B | -$3.6B | $2B | $1.9B | $971M | |
| Cash From Investing | -$3.6B | -$3.8B | $1.6B | -$1.5B | $980M | |
| Cash From Financing | -$776M | -$2.6B | -$3.4B | -$770M | -$603M | |
| Free Cash Flow | $5B | -$4.3B | $1.5B | $1.7B | $836M | |
HUM
Sector
Market Cap
$31.2B
$27.9M
Price % of 52-Week High
82.26%
51.04%
Dividend Yield
1.37%
0%
Shareholder Yield
2.05%
-1.49%
1-Year Price Total Return
10.02%
-16.66%
Beta (5-Year)
0.462
0.516
Dividend yield:
1.37%
Annualized payout:
$3.54
Payout ratio:
54.8%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$263.11
200-day SMA
Buy
Level
$258.63
Bollinger Bands (100)
Sell
Level
246.99 - 290.77
Chaikin Money Flow
Buy
Level
313.4M
20-day SMA
Buy
Level
$252.48
Relative Strength Index (RSI14)
Buy
Level
52.39
ADX Line
Buy
Level
17.36
Williams %R
Neutral
Level
-43.0901
50-day SMA
Sell
Level
$260.12
MACD (12, 26)
Buy
Level
2.58
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
141.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.471)
Buy
CA Score
(Annual)
Level (0.0076)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.0606)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.
Stock Forecast FAQ
In the current month, HUM has received 7 Buy ratings 16 Hold ratings, and 1 Sell ratings. The HUM average analyst price target in the past 3 months is $287.83.
-
Where Will Humana, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Humana, Inc. share price will rise to $287.83 per share over the next 12 months.
-
What Do Analysts Say About Humana, Inc.?
Analysts are divided on their view about Humana, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Humana, Inc. is a Sell and believe this share price will drop from its current level to $215.00.
-
What Is Humana, Inc.'s Price Target?
The price target for Humana, Inc. over the next 1-year time period is forecast to be $287.83 according to 24 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 16 analysts rate the stock a Hold.
-
Is HUM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Humana, Inc. is a Hold. 16 of 24 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HUM?
You can purchase shares of Humana, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Humana, Inc. shares.
-
What Is The Humana, Inc. Share Price Today?
Humana, Inc. was last trading at $257.90 per share. This represents the most recent stock quote for Humana, Inc.. Yesterday, Humana, Inc. closed at $259.40 per share.
-
How To Buy Humana, Inc. Stock Online?
In order to purchase Humana, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HUM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HUM
Sector
P/E ratio
24.31x
23.85x
PEG ratio
--
-0.01x
P/B ratio
1.68x
1.81x
Price / LTM sales
0.25x
1.58x
Growth Metrics
HUM
Sector
Revenue growth
11.06%
4.62%
Earnings growth
-59.37%
10.7%
Revenue (5-year growth)
12.65%
6.5%
Earnings forecast
$2.83
-$0.21
Profitability
HUM
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
4.25%
-31.87%
Return on assets
2.62%
-28.18%
Return on equity
7.3%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Feb
4
Balance Sheet
HUM
Sector
Total cash
$21.7B
$26.4M
Short term investments
$18.2B
$25.7M
Total assets
$46.3B
$76.9M
Long term debt
$12.6B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 1.82% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.22% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.8% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
